Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| ACCURIDE CORP | 128,834 | reported | 18 Nov 2016 | tx 40+342,542−385,406 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 18 Nov 2016 | TAX_WITHHOLDING | ACCURIDE CORP | 44,434 | 2.58 USD | |
| 18 Nov 2016 | OTHER | ACCURIDE CORP | 128,834 | 2.58 USD | |
| 18 Nov 2016 | EXERCISE | ACCURIDE CORP | 139,516 | 0.00 USD | |
| 18 Nov 2016 | EXERCISE | ACCURIDE CORP | 139,516 | 0.00 USD | deriv |
| 10 Mar 2016 | GRANT_AWARD | ACCURIDE CORP | 37,729 | 0.00 USD | deriv |
| 05 Mar 2016 | TAX_WITHHOLDING | ACCURIDE CORP | 2,159 | 1.80 USD | |
| 05 Mar 2016 | TAX_WITHHOLDING | ACCURIDE CORP | 1,883 | 1.80 USD | |
| 05 Mar 2016 | EXERCISE | ACCURIDE CORP | 5,849 | 0.00 USD | |
| 05 Mar 2016 | EXERCISE | ACCURIDE CORP | 5,095 | 0.00 USD | |
| 05 Mar 2016 | TAX_WITHHOLDING | ACCURIDE CORP | 1,881 | 1.80 USD | |
| 05 Mar 2016 | EXERCISE | ACCURIDE CORP | 8,438 | 0.00 USD | |
| 05 Mar 2016 | TAX_WITHHOLDING | ACCURIDE CORP | 3,114 | 1.80 USD | |
| 05 Mar 2016 | EXERCISE | ACCURIDE CORP | 5,101 | 0.00 USD | |
| 05 Mar 2016 | EXERCISE | ACCURIDE CORP | 5,849 | 0.00 USD | deriv |
| 05 Mar 2016 | EXERCISE | ACCURIDE CORP | 8,438 | 0.00 USD | deriv |
| 05 Mar 2016 | EXERCISE | ACCURIDE CORP | 5,101 | 0.00 USD | deriv |
| 05 Mar 2016 | EXERCISE | ACCURIDE CORP | 5,095 | 0.00 USD | deriv |
| 05 Mar 2015 | EXERCISE | ACCURIDE CORP | 5,849 | 0.00 USD | |
| 05 Mar 2015 | TAX_WITHHOLDING | ACCURIDE CORP | 1,882 | 4.97 USD | |
| 05 Mar 2015 | EXERCISE | ACCURIDE CORP | 5,100 | 0.00 USD | |
| 05 Mar 2015 | TAX_WITHHOLDING | ACCURIDE CORP | 1,356 | 4.97 USD | |
| 05 Mar 2015 | EXERCISE | ACCURIDE CORP | 4,218 | 0.00 USD | |
| 05 Mar 2015 | TAX_WITHHOLDING | ACCURIDE CORP | 2,159 | 4.97 USD | |
| 05 Mar 2015 | EXERCISE | ACCURIDE CORP | 5,100 | 0.00 USD | deriv |
| 05 Mar 2015 | EXERCISE | ACCURIDE CORP | 5,849 | 0.00 USD | deriv |